COVID-19 natural product trial: Proposed curcumin-artemisinin supplement tested on patients
A curcumin and artemisinin-based oral spray was proposed as a treatment for COVID-19 patients and a clinical trial to be conducted in April, ASX-listed phytocannabinoid firm MGC Pharmaceuticals revealed.
Known as ArtemiC, the new product was jointly developed by MGC and Switzerland firm Micelle Technology based on a product originally developed by the latter. New adaptations have been made to the product in response to COVID-19.
The supplement, which also contains vitamin C and Boswellia serrata, would be tested on COVID-19 patients in Israel’s Nazareth Hospital EMMS.
The double-blind, placebo-controlled, two-week clinical trial started in April and expected to recruit 50 patients between 40 and 75 years old.